In October 2020, the Pharmaceutical Advertising Advisory Board (PAAB) released an advisory addressing references to "no sub" or "no substitution" in advertising materials. The advisory states that advertisers are permitted to indicate in promotional material that prescribers can write "no sub" on a prescription but should not suggest that writing "no sub" will guarantee that the patient will receive the prescribed brand name product. A patient may not end up receiving such product for a variety of reasons, including the patient opting for a generic product and due to conditions for reimbursement. A disclaimer indicating limitations and conditions should also be included as part of the fair balance requirement under the PAAB Code of Advertising Acceptance. The advisory provides an example of language that is acceptable and language that is not acceptable to include in promotional material and an example of a disclaimer.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.